Staphylococcus aureus (S. aureus) - Articles and news items

Antibiotics: resist the resistance

Blog, Z Homepage promo / 15 September 2016 / Niamh Louise Marriott, Digital Content Producer

European Pharmaceutical Review caught up with Destiny Pharma’s CEO, Dr Love, for an exclusive interview to discuss why the pharmaceutical industry needs to radically change its approach to antibiotics in order to combat the threat of bacterial resistance…

FDA approves label update for Teflaro

Industry news / 2 September 2015 / Victoria White

Teflaro is now approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia…

Aridis expands Phase 2a trial of AR-301 into the US

Industry news / 9 July 2015 / Victoria White

The US Food and Drug Administration (FDA) has accepted Aridis Pharmaceuticals’ Investigational New Drug (IND) application for AR-301 (Salvecin)…

Pfizer begins Phase 2b study of S. aureus vaccine in adults undergoing elective spinal fusion surgery

Industry news / 7 July 2015 / Victoria White

The first patients have been enrolled in a Phase 2b clinical trial of Pfizer’s S. aureus vaccine in adults undergoing elective spinal fusion surgery…

Nabriva Therapeutics presents data on lefamulin at ECCMID 2015

Industry news / 27 April 2015 / Victoria White

Three posters on the Extended Spectrum Pleuromutilins (ESP) Programme and one poster on lefamulin were presented at ECCMID 2015…


Changing the way we combat bacterial infections: Dutch biotech Micreos launches first bacteria-killing enzyme for human use against MRSA

Industry news / 5 November 2014 / Micreos

Micreos, a Dutch biotech company, has developed Staphefekt™, a bacteria-killing enzyme specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant Staphylococcus aureus (MRSA) as methicillin-susceptible Staphylococcus aureus (MSSA)…

Merck logo

Merck receives approval to market GARDASIL®, ZOLINZA® and CUBICIN®

Industry news, News / 1 July 2011 / Merck

Merck announced that the Japanese MHLW approved three products – GARDASIL®, ZOLINZA® and CUBICIN®…

Merck logo

Merck and Intercell terminate Phase II/III clinical trial of V710

Industry news / 8 June 2011 / Merck

DMC recommends termination of the evaluation of investigational Staphylococcus aureus vaccine, V710…

Staphylococcus aureus

Update on Phase II/III clinical trial of investigational staphylococcus aureus vaccine, V710

Industry news, News / 11 April 2011 / Merck

After a pre-specified interim analysis the DMC has recommended suspension of enrollment…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...